Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 1;28(1):3-6.
doi: 10.1097/LGT.0000000000000788.

2019 ASCCP Risk-Based Management Consensus Guidelines: Updates Through 2023

Rebecca B Perkins  1 , Richard S Guido  2 , Philip E Castle  3 , David Chelmow  4 , Mark H Einstein  5 , Francisco Garcia  6 , Warner K Huh  7 , Jane J Kim  8 , Anna-Barbara Moscicki  9 , Ritu Nayar  10 , Mona Saraiya  11 , George F Sawaya  12 , Nicolas Wentzensen  3 , Mark Schiffman  3 ; 2019 ASCCP Risk-Based Management Consensus Guidelines Committee
Collaborators, Affiliations

2019 ASCCP Risk-Based Management Consensus Guidelines: Updates Through 2023

Rebecca B Perkins et al. J Low Genit Tract Dis. .

Abstract

This Research Letter summarizes all updates to the 2019 Guidelines through September 2023, including: endorsement of the 2021 Opportunistic Infections guidelines for HIV+ or immunosuppressed patients; clarification of use of human papillomavirus testing alone for patients undergoing observation for cervical intraepithelial neoplasia 2; revision of unsatisfactory cytology management; clarification that 2012 guidelines should be followed for patients aged 25 years and older screened with cytology only; management of patients for whom colposcopy was recommended but not completed; clarification that after treatment for cervical intraepithelial neoplasia 2+, 3 negative human papillomavirus tests or cotests at 6, 18, and 30 months are recommended before the patient can return to a 3-year testing interval; and clarification of postcolposcopy management of minimally abnormal results.

PubMed Disclaimer

Conflict of interest statement

The following listed authors have conflicts of interest: The other authors have declared they have no conflicts of interest.

Figures

FIGURE 7
FIGURE 7
(of the originally published paper) Management of histologic HSIL (CIN2 or CIN3 or Not Further Specified)*. CIN, cervical intraepithelial neoplasia; HSIL, high-grade squamous intraepithelial lesion. Figures 7 and 8 originally published in Perkins et al.
FIGURE 8
FIGURE 8
(of the originally published paper) Management of CIN2 at age younger than 25 years or for those concerned about the effects of treatment on future pregnancy. Figures 7 and 8 originally published in Perkins et al.
See this image and copyright information in PMC

References

    1. Perkins RB Guido RS Castle PE, et al. . 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J Low Genit Tract Dis 2020;24:102–31. - PMC - PubMed
    1. National Cancer Institute . Enduring Consensus Cervical Cancer Screening and Management Guidelines. Available at: https://dceg.cancer.gov/research/cancer-types/cervix/enduring-guidelines. Accessed October 10, 2022.
    1. Perkins RB Guido RS Castle PE, et al. . Erratum: 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J Low Genit Tract Dis 2021;25:330–1. - PubMed
    1. Perkins RB Guido RL Castle PE, et al. . Response to Letter to the Editor regarding: 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J Low Genit Tract Dis 2020;24:426–6. - PubMed
    1. Egemen D Perkins RB Clarke MA, et al. . Risk-based cervical consensus guidelines: methods to determine management if less than 5 years of data are available. J Low Genit Tract Dis 2022;26:195–201. - PMC - PubMed